TL;DR
It is identified that RBM15/IFI6 axis is a novel m6A-dependent pathway driving BLCA progression, offering a potential therapeutic target for BLCA.
Clinically, these findings identify the METTL1/USP48/LCN2 pathway as a potential therapeutic target for cSCC and elucidated a novel oncogenic axis in cSCC, wherein METTL1 stabilized USP48 mRNA through m7G methylation modification, and USP48 in turn deubiquitinated and stabilized LCN2 protein.
KIAA1429 knockdown may suppress OS progression by inhibiting m6A-dependent SLC7A11 expression, thereby promoting ferroptosis and targeting the KIAA1429/SLC7A11 axis may represent a promising therapeutic strategy for OS.
Background: Triple-negative breast cancer (TNBC) is exceptionally aggressive, with a high recurrence rate, resistance to chemotherapy, and a tendency to metastasize. The long non-coding RNA growth arrest-specific 5 (GAS5) is associated with TNBC progression; however, the specific mechanism still requires further explor...
ABSTRACT 5‐Methylcytosine (m5C) is a vital RNA modification that regulates mRNA stability, splicing, and nuclear export. As a key m5C reader, ALYREF promotes tumorigenesis across various cancers; however, its precise role in endometrial cancer (EC) remains unknown. ALYREF expression and clinical significance in EC were...
An ERα/HNRNPC/DDX6 axis in ER+ breast cancer is unveiled, wherein ERα transcriptionally upregulates HNRNPC, which in turn stabilizes DDX6 mRNA in an m6A-dependent manner to drive tumor progression, suggesting HNRNPC as a promising therapeutic target.
The findings establish the TRIM2-DTNBP1 axis as a key driver of PCa progression and position TRIM2 as a promising prognostic biomarker and a potential predictive indicator for guiding molecularly targeted therapies in advanced PCa.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
